Hide metadata

dc.contributor.authorLangerød, Anita
dc.contributor.authorZhao, Hongjuan
dc.contributor.authorBorgan, Ørnulf
dc.contributor.authorNesland, Jahn M
dc.contributor.authorBukholm, Ida R
dc.contributor.authorIkdahl, Tone
dc.contributor.authorKåresen, Rolf
dc.contributor.authorBørresen-Dale, Anne-Lise
dc.contributor.authorJeffrey, Stefanie S
dc.date.accessioned2015-10-09T02:09:23Z
dc.date.available2015-10-09T02:09:23Z
dc.date.issued2007
dc.identifier.citationBreast Cancer Research. 2007 May 15;9(3):R30
dc.identifier.urihttp://hdl.handle.net/10852/46618
dc.description.abstractIntroduction Gene expression profiling of breast carcinomas has increased our understanding of the heterogeneous biology of this disease and promises to impact clinical care. The aim of this study was to evaluate the prognostic value of gene expression-based classification along with established prognostic markers and mutation status of the TP53 gene (tumour protein p53) in a group of breast cancer patients with long-term (12 to 16 years) follow-up. Methods The clinical and histopathological parameters of 200 breast cancer patients were studied for their effects on clinical outcome using univariate/multivariate Cox regression. The prognostic impact of mutations in the TP53 gene, identified using temporal temperature gradient gel electrophoresis and sequencing, was also evaluated. Eighty of the samples were analyzed for gene expression using 42 K cDNA microarrays and the patients were assigned to five previously defined molecular expression groups. The strength of the gene expression based classification versus standard markers was evaluated by adding this variable to the Cox regression model used to analyze all samples. Results Both univariate and multivariate analysis showed that TP53 mutation status, tumor size and lymph node status were the strongest predictors of breast cancer survival for the whole group of patients. Analyses of the patients with gene expression data showed that TP53 mutation status, gene expression based classification, tumor size and lymph node status were significant predictors of survival. Breast cancer cases in the 'basal-like' and 'ERBB2+' gene expression subgroups had a very high mortality the first two years, while the 'highly proliferating luminal' cases developed the disease more slowly, showing highest mortality after 5 to 8 years. The TP53 mutation status showed strong association with the 'basal-like' and 'ERBB2+' subgroups, and tumors with mutation had a characteristic gene expression pattern. Conclusion TP53 mutation status and gene-expression based groups are important survival markers of breast cancer, and these molecular markers may provide prognostic information that complements clinical variables. The study adds experience and knowledge to an ongoing characterization and classification of the disease.
dc.language.isoeng
dc.rightsLangerød et al.; licensee BioMed Central Ltd.
dc.rightsAttribution 2.0 Generic
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/
dc.titleTP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
dc.typeJournal article
dc.date.updated2015-10-09T02:09:23Z
dc.creator.authorLangerød, Anita
dc.creator.authorZhao, Hongjuan
dc.creator.authorBorgan, Ørnulf
dc.creator.authorNesland, Jahn M
dc.creator.authorBukholm, Ida R
dc.creator.authorIkdahl, Tone
dc.creator.authorKåresen, Rolf
dc.creator.authorBørresen-Dale, Anne-Lise
dc.creator.authorJeffrey, Stefanie S
dc.identifier.doihttp://dx.doi.org/10.1186/bcr1675
dc.identifier.urnURN:NBN:no-50799
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46618/1/13058_2006_Article_1640.pdf
dc.type.versionPublishedVersion
cristin.articleidR30


Files in this item

Appears in the following Collection

Hide metadata

Attribution 2.0 Generic
This item's license is: Attribution 2.0 Generic